Evoke Pharma Inc (EVOK) USD0.0001

Sell:$3.60Buy:$4.00$0.17 (4.48%)

Prices delayed by at least 15 minutes
Sell:$3.60
Buy:$4.00
Change:$0.17 (4.48%)
Prices delayed by at least 15 minutes
Sell:$3.60
Buy:$4.00
Change:$0.17 (4.48%)
Prices delayed by at least 15 minutes

Company Information

About this company

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.

Key people

Matthew J. D'Onofrio
President, Chief Executive Officer, Treasurer, Secretary, Director
Mark A. Kowieski
Chief Financial Officer
Marilyn R. Carlson
Chief Medical Officer
Cam L. Garner
Independent Chairman of the Board
Todd C. Brady
Independent Director
Malcolm R. Hill
Independent Director
Greg Pyszcymuka
Independent Director
Vickie W. Reed
Independent Director
Click to see more

Key facts

  • EPIC
    EVOK
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US30049G3020
  • Market cap
    $5.71m
  • Employees
    4
  • Shares in issue
    1.49m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.